Skip to content
Peptide.Guide
EstablishedGLP-1 & IncretinSubQTwice daily or weekly per formulation

Exenatide

Byetta · Bydureon · Bydureon BCise · Exendin-4

The first GLP-1 receptor agonist ever approved (2005), originally derived from Gila monster venom (exendin-4). Available in twice-daily (Byetta) and once-weekly extended-release (Bydureon) formulations.

Read dosing protocolJump to references

§ 01   Overview

Overview

The first GLP-1 receptor agonist ever approved (2005), originally derived from Gila monster venom (exendin-4). Available in twice-daily (Byetta) and once-weekly extended-release (Bydureon) formulations.

Byetta approved April 2005 (first GLP-1 agonist). Bydureon approved January 2012. EXSCEL CVOT (N=14,752) showed CV non-inferiority but not superiority. Weight loss typically 2–4 kg. Largely superseded by semaglutide and tirzepatide clinically but remains historically important.

§ 02   Mechanism

Mechanism of action

Synthetic exendin-4, a 39-amino-acid peptide originally isolated from Heloderma suspectum saliva. Shares 53% homology with native GLP-1 but resists DPP-4 degradation, giving a much longer duration of action. Activates GLP-1R for glucose-dependent insulin secretion, glucagon suppression, and gastric emptying delay.

  • 01First-in-class GLP-1 agonist; the drug that proved the GLP-1 concept
  • 02Extended-release (Bydureon) enables weekly dosing
  • 0320+ years of clinical safety data
  • 04Unique non-human sequence (exendin-4) with intrinsic DPP-4 resistance

§ 03   Dosing

Dosing protocol

Standard Protocol

Vial
5 / 10 mcg pen (Byetta); 2 mg ER pen (Bydureon)
BAC Water
N/A; pre-filled
Dose Range
5–10 mcg twice daily (Byetta); 2 mg weekly (Bydureon)
Starting Dose
5 mcg twice daily for 1 month, then 10 mcg
Route
SubQ
Timing
Byetta: within 60 min of AM/PM meals. Bydureon: any day of week
Frequency
Twice daily or weekly per formulation
Cycle
Continuous use

Storage

Refrigerate unused.

§ 04   Evidence

Evidence & research

Established

Byetta approved April 2005 (first GLP-1 agonist). Bydureon approved January 2012. EXSCEL CVOT (N=14,752) showed CV non-inferiority but not superiority. Weight loss typically 2–4 kg. Largely superseded by semaglutide and tirzepatide clinically but remains historically important.

FDA Status

FDA-approved (Byetta NDA 021773, 2005; Bydureon BLA 022200, 2012).

§ 06   News

In the news

8 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

FDA-approved

This compound has an FDA approval for at least one indication. Brand pharmacy channels exist. Compounding may or may not be available depending on shortage status.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09   Safety

Safety & side effects

Side effects

  • 01Nausea (very common with Byetta)
  • 02Injection site nodules (Bydureon)
  • 03Hypoglycemia when combined with sulfonylureas or insulin

Contraindications

  • 01Severe GI disease or gastroparesis
  • 02End-stage renal disease
  • 03History of pancreatitis

§ 10   Questions

Exenatide FAQ

What is Exenatide?
The first GLP-1 receptor agonist ever approved (2005), originally derived from Gila monster venom (exendin-4). Available in twice-daily (Byetta) and once-weekly extended-release (Bydureon) formulations. Synthetic exendin-4, a 39-amino-acid peptide originally isolated from Heloderma suspectum saliva. Shares 53% homology with native GLP-1 but resists DPP-4 degradation, giving a much longer duration of action. Activates GLP-1R for glucose-dependent insulin secretion, glucagon suppression, and gastric emptying delay.
What is Exenatide used for?
Reported uses include first-in-class glp-1 agonist; the drug that proved the glp-1 concept, extended-release (bydureon) enables weekly dosing, 20+ years of clinical safety data, and unique non-human sequence (exendin-4) with intrinsic dpp-4 resistance. Evidence strength is rated Established — see the evidence section for detail.
How is Exenatide dosed?
Commonly referenced dosing is 5–10 mcg twice daily (Byetta); 2 mg weekly (Bydureon), typically twice daily or weekly per formulation, administered SubQ. This is educational reference only; consult a licensed clinician before use.
How do you reconstitute Exenatide?
For Exenatide, vials commonly come in 5 / 10 mcg pen (Byetta); 2 mg ER pen (Bydureon) and a common reconstitution is N/A; pre-filled. Use the reconstitution calculator to convert any vial size and water volume into exact insulin-syringe units.
What are the side effects of Exenatide?
Commonly reported side effects include nausea (very common with byetta), injection site nodules (bydureon), and hypoglycemia when combined with sulfonylureas or insulin. This list is not exhaustive.
Is Exenatide legal?
This compound has an FDA approval for at least one indication. Brand pharmacy channels exist. Compounding may or may not be available depending on shortage status. FDA status: FDA-approved (Byetta NDA 021773, 2005; Bydureon BLA 022200, 2012)..

§ 11   References

Selected references

  1. 01

    EXSCEL CVOT

    PMID: 28881995 (NCT01144338)

  2. 02

    DURATION-1 (weekly)

    PMID: 18819705

◆   In this categoryMore from GLP-1 & Incretin
01

Semaglutide

Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with established cardiovascular benefit.

Established
02

Tirzepatide

Dual GIP/GLP-1 receptor agonist producing greater average weight loss than semaglutide in head-to-head trials.

Established
03

Retatrutide

Investigational triple agonist (GLP-1, GIP, glucagon) producing the largest weight loss seen in Phase II trials to date.

Clinical
04

Cagrilintide

Long-acting amylin analog that slows gastric emptying and enhances satiety, typically paired with semaglutide (CagriSema).

Clinical
05

Mazdutide

Dual GLP-1 / glucagon receptor agonist showing strong weight loss and metabolic effects in late-stage trials, particularly in Asian populations.

Clinical

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.